Palavras-chave
Coronavírus
Sistema cardiovascular
Como Citar
Resumo
A infecção por COVID-19 é conhecida pelas implicações respiratórias, contudo as complicações multissistêmicas, como problemas cardiovasculares, devem ser consideradas. Até o momento, há uma escassez na compreensão das implicações da infecção por COVID-19 no sistema cardiovascular, sendo, o objetivo do presente estudo realizar uma revisão sistemática de literatura para analisar esta temática. O estudo seguiu as diretrizes PRISMA, sendo pesquisado nos bancos de dados Cochrane Library e PubMed artigos publicados até 2022 e utilizando descritores como “COVID”, “Coronavírus”, “Doença cardiovascular”, “COVID longo”. Do total de 4.538 artigos encontrados inicialmente, após aplicação dos critérios de inclusão e exclusão, 9 estudos foram incluídos na revisão. As evidências indicam implicações cardiovasculares em pacientes pós-infecção por COVID-19, sendo necessárias estratégias adequadas e eficazes para reconhecer a natureza aguda e crônica dessas implicações e para lidar com a cronicidade e a morbidade.
Referências
Coccolini F., Cicuttin E., Cremonini C., et al. A pandemic recap: lessons we have learned. World J Emerg Surg. 2021;16(1):46.
Stenseth N.C., Dharmarajan G., Li R., et al. Lessons learnt from the COVID-19 pandemic. Front Public Health. 2021;9.
Stenseth N.C., Dharmarajan G., Li R., et al. Lessons learnt from the COVID-19 pandemic. Front Public Health. 2021;9
Elliott J., Whitaker M., Bodinier B., et al. Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLoS Med. 2021;18(9).
Kompaniyets L., Pennington A.F., Goodman A.B., et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:E66.
Li B., Yang J., Zhao F., et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538.
Sanyaolu A., Marinkovic A., Prakash S., et al. Post-acute sequelae in COVID-19 survivors: an overview. SN Compr Clin Med. 2022;4(1):91.
Welty F.K., Rajai N., Amangurbanova M. Comprehensive review of cardiovascular complications of coronavirus disease 2019 and beneficial treatments. Cardiol Rev. 2022;30(3):145–157.
Schmid A., Petrovic M., Akella K., Pareddy A., Velavan S.S. Getting to the heart of the matter: myocardial injury, coagulopathy, and other potential cardiovascular implications of COVID-19. Int J Vasc Med. 2021;2021:6693895.
Moher D et al.. Preferred reporting items for systematic reviews and Meta-Analyses: the PRISMA statement (reprinted from annals of internal medicine). Phys Ther. 2009;89(9):873–880.
Barco S., Voci D., Held U., et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol. 2022;9(8):e585–e593.
Connors J.M., Brooks M.M., Sciurba F.C., et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. Jama. 2021;326(17):1703–1712.
Foged F., Rasmussen I.E., Bjørn Budde J., et al. Fidelity, tolerability and safety of acute high-intensity interval training after hospitalisation for COVID-19: a randomised cross-over trial. BMJ Open Sport Exerc Med. 2021;7(3)
Gonzalez-Ochoa A.J., Raffetto J.D., Hernández A.G., et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. 2021;121(7):944–954.
Leucker T.M., Osburn W.O., Reventun P., et al. Effect of crizanlizumab, a P-selectin inhibitor, in COVID-19: a placebo-controlled, randomized trial. JACC Basic Transl Sci. 2021;6(12):935–945.
Lopes R.D., Macedo A.V.S., de Barros E.S.P.G.M., et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254–264.
Poncin W., Schalkwijk A., Vander Straeten C., et al. Impact of surgical mask on performance and cardiorespiratory responses to submaximal exercise in COVID-19 patients near hospital discharge: a randomized crossover trial. Clin Rehabil. 2022;36(8):1032–1041.
Sholzberg M., Tang G.H., Rahhal H., et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. Bmj. 2021;375.
Teixeira D.O.A.V., Viana A.A., Heubel A.D., et al. Cardiovascular, respiratory, and functional effects of home-based exercise training after COVID-19 hospitalization. Med Sci Sports Exerc. 2022;54(11):1795–1803.
Cenko E., Badimon L., Bugiardini R., et al. Cardiovascular disease and COVID-19: a consensus paper from the ESC working group on Coronary Pathophysiology & Microcirculation, ESC working group on thrombosis and the Association for Acute CardioVascular care (ACVC), in collaboration with the European heart rhythm association (EHRA) Cardiovasc Res. 2021;117(14):2705–2729.
Goyal P., Choi J.J., Pinheiro L.C., et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
Krishna H., Ryu A.J., Scott C.G., et al. Cardiac abnormalities in COVID-19 and relationship to outcome. Mayo Clin Proc. 2021;96(4):932–942.
Arévalos V., Ortega-Paz L., Rodríguez-Arias J.J., et al. Acute and chronic effects of COVID-19 on the cardiovascular system. J Cardiovasc Dev Dis. 2021;8(10).
Umbrajkar S., Stankowski R.V., Rezkalla S., Kloner R.A. Cardiovascular health and disease in the context of COVID-19. Cardiol Res. 2021;12(2):67–79.
Guzik T.J., Mohiddin S.A., Dimarco A., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
Wulf Hanson S., Abbafati C., Aerts J.G., et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. medRxiv. 2022.
Cutler D.M. The costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809.
Faghy M.A., Owen R., Thomas C., et al. Is long COVID the next global health crisis? Journal of. Glob Health. 2022:12.
Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232.
Tronco Hernández Y.A., Parente F., Faghy M.A., Roscoe C.M.P., Maratos F.A. Influence of the COVID-19 lockdown on the physical and psychosocial well-being and work productivity of remote workers: cross-sectional correlational study. JMIRx Med. 2021;2(4).
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Giovanna Gabriela Santos Felix Cavalcanti , Ana Claudia Rodrigues da Silva , Ayara Almeida Souza Cabral , Bruna Rafaela da Silva Santos , Natalha Cabral do Nascimento , Camila Yohanna Lira Sousa , Alycia Antunes de Carvalho , Alynne Saphira Araújo Costa , Ailla Gabrielli Costa Silva , Rafael Pereira dos Santos , Teresa Victória Costa da Silva , Felipe Cardoso Rodrigues Vieira